IBRX News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

IB

Mkt Cap

$10.60B

Volume

20.09M

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

FDA Expands ImmunityBio's Anktiva Label in Bladder CancerImmunityBio received FDA approval to expand Anktiva's label for treating BCG-unresponsive non-muscle-invasive bladder cancer with high-grade papillary-only disease. The approval, granted three months ahead of schedule, now covers all BCG-unresponsive NMIBC patients. Anktiva sales surged 121% year-over-year to $95 million in the first half of 2026, driven by strong physician adoption and new prescriber demand.Zacks Investment Research · Oct 15, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRXPomerantz Law Firm has filed class action lawsuits against ImmunityBio, Inc., New Era Energy & Digital, Inc., and Vital Farms, Inc. for alleged securities fraud and unlawful business practices. The primary case involves ImmunityBio, which faced an FDA warning letter on March 24, 2026, for continuing to promote its bladder-cancer drug Anktiva in a misleading manner despite previous warnings. The disclosure triggered a 21.12% stock price decline. Investors have until May 26, 2026, to request Lead Plaintiff status.GlobeNewswire Inc. · May 26, 2026

IBRX DEADLINE TOMORROW: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRXRosen Law Firm reminds ImmunityBio investors of the May 26, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that defendants made false and misleading statements about Anktiva's capabilities and ImmunityBio's business operations. Investors who purchased securities between January 19, 2026 and March 24, 2026 may be entitled to compensation.GlobeNewswire Inc. · May 25, 2026

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law FirmThe Schall Law Firm is seeking investors who purchased ImmunityBio securities between January 19, 2026 and March 24, 2026 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements about its Anktiva drug capabilities, causing investor losses when the truth was revealed.GlobeNewswire Inc. · May 25, 2026

IBRX DEADLINE NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRXRosen Law Firm announces securities class action lawsuits against ImmunityBio, Inc. and other companies for allegedly making false and misleading statements. The firm is seeking lead plaintiffs with losses exceeding $100,000 before the May 26, 2026 deadline. According to the lawsuit, ImmunityBio's defendant Patrick Soon-Shiong materially overstated Anktiva's capabilities, resulting in false statements about the company's business and prospects.GlobeNewswire Inc. · May 22, 2026

IBRX 4-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims – Hagens BermanImmunityBio (IBRX) is facing a securities class action lawsuit after the FDA issued a warning letter regarding misleading efficacy claims made by executive chairman Dr. Patrick Soon-Shiong about the company's drug Anktiva. The FDA determined that promotional materials falsely suggested Anktiva could treat all cancers, when it is only approved for non-muscle invasive bladder cancer. The announcement caused IBRX shares to plunge over 21% on March 24, 2026, erasing nearly $2 billion in market capitalization. Hagens Berman is investigating claims that ImmunityBio intentionally misled investors.GlobeNewswire Inc. · May 22, 2026

Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor HarmA class action lawsuit has been filed against ImmunityBio, Inc. (NASDAQ: IBRX) alleging that company defendants made materially false and misleading statements regarding Anktiva's capabilities and the company's business prospects. The lawsuit covers investors who purchased ImmunityBio securities between January 19, 2026 and March 24, 2026. The lead plaintiff deadline is May 26, 2026.GlobeNewswire Inc. · May 20, 2026

ImmunityBio Stock Climbs As FDA Accepts Expanded Use Filing For Bladder Cancer DrugImmunityBio's stock rose 8.12% in premarket trading after the FDA accepted its supplemental Biologics License Application (sBLA) for ANKTIVA in combination with BCG for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The FDA assigned a PDUFA target action date of January 6, 2027. The Phase 2/3 QUILT 3.032 trial demonstrated strong efficacy with a 12-month disease-free survival rate of 58.2% and 96.0% disease-specific survival at 36 months.Benzinga · May 20, 2026

ImmunityBio Says ANKTIVA Combo Outperformed Rival Bladder Cancer TherapiesImmunityBio presented comparative analyses showing its ANKTIVA plus BCG combination achieved higher complete response rates (69.7%) against nadofaragene firadenovec-vncg (53.4%) and longer response duration (22.1 vs 9.7 months). Against TAR-200, ANKTIVA showed comparable efficacy with significantly fewer adverse events (61.7% vs 83.5%), representing a 68% reduction in treatment-related side effects for BCG-unresponsive bladder cancer patients.Benzinga · May 19, 2026

IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urges Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights Before May 26thA class action lawsuit has been filed against ImmunityBio, Inc. (NASDAQ: IBRX) in the U.S. District Court for the Central District of California. The lawsuit alleges that defendants made false and misleading statements regarding Anktiva's capabilities and the company's business operations during the Class Period (January 19, 2026 - March 24, 2026). Investors who purchased ImmunityBio securities during this period and suffered losses have until May 26, 2026, to apply to be appointed as lead plaintiff.GlobeNewswire Inc. · May 18, 2026

IB

IBRXImmunityBio, Inc. Common Stock

IBRX

Pay with—

Available Balance0.00

Your PositionYou don't own any IBRX yet.

Related Tickers

Earnings